CClinicalTrials.gg
TerminatedNCT03365076EXIPOXUpdated Jan 9, 2023

Exercise for Improving Prostate Oxygenation in Prostate Tumors (Exipox)

An interventional study of Physical activity in Prostate Cancer, Physical Activity and Hypoxia, sponsored by University Hospital of North Norway. Terminated at 1 site in Norway. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-01-09.

Sponsored by University Hospital of North Norway · Not applicable, Interventional, and Treatment

Why this study was terminated
Slow inclusion rate due to patients operated before intervention is implementable
Phase
Not applicable
Study type
Interventional
Enrollment
1
Allocation
Randomized
Ages
18 Years and older
Sex
Male
01

Study summary

Previous research into metabolic and hypoxic markers has found evidence of preclinical impact of exercise on prostate tumor blood flow and oxygenation in rodents . As radiotherapy is a frequently used and effective therapy for and that sufficient oxygenation is decisive to the effect of radiotherapy, an underlying hypothesis that aerobic exercise might improve treatment efficacy of radiotherapy in prostate cancer is put forward. This study has a potential challenging intervention, but a potential very high gain as it includes active patient participation to significantly improve outcome of radical radiotherapy.

Read the detailed description

A randomized controlled trial with four to five weeks of moderate/high intensity aerobic exercise program compared with no intervention for 32 prostate cancer patients waiting for radical prostatectomy at the University Hospital of North Norway (UNN). 16 patients will undergo the intervention. The expression of the hypoxic marker pimonidazole in the prostate specimens of intervention groups and the control groups will be assessed. This method is considered a reliable tissue oxygenation measurement technique. These patients will also have their and blood flow and hypoxia measured in prostate cancers through magnetic resonance imaging (MRIs).

02

Conditions studied

  • Prostate Cancer
  • Physical Activity
  • Hypoxia
03

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Inclusion criteria

  • diagnosed PC
  • planned radical prostatectomy
  • informed consent given
  • above 18 years of age
  • BMI \< 30
  • non-smoker
  • living in Tromso region

Exclusion criteria

Exclusion Criteria:

  • Contraindications to the intervention like;

    • heart failure,
    • angina pectoris,
    • respiratory disease limiting possible intervention
    • use of physical supportive devices to aid movement
  • High level of physical activity
  • smoking
  • BMI>30
04

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
1 participant (actual)

Study arms

  • Experimental
    Physical aerobic intervention

    The exercise program will be varying between different aerobic activities indoor or outdoor as walking uphill and in stairs in intervals that will differ from session to session to build up the load and progression for these patients. In total, each session will be lasting approximately 45-60 minutes and a physiotherapist or personal trainer will supervise each session. Depending on the participants starting point, there will be 3 supervised session per week and two sessions where the participants do activity with low intensity (walk) by themselves and keep a log with duration (time) and intensity (using Borg scale).

    Other: Physical activity

  • No intervention
    Controls

    These patients will be acting as controls by not been instructed to physical activity. We will not monitor their activity either as this has been shown to increase activity by itself.

Interventions

  • OtherPhysical activity

    Aerobic physical activity as stated in Arm A

05

What researchers measure

Primary outcomes

  1. Hypoxic fraction-gold standard

    We will measure the hypoxic fraction in prostate cancer specimens by pimonidazole

    Time frame: through study completion, an average of 1 year

Secondary outcomes

  1. Side effects

    We will use the Expanded Prostate Cancer Index Composite (EPIC) designed to evaluate patient function and side effects after PC treatment in both groups

    Time frame: through study completion, an average of 1 year

  2. Hypoxic fraction-MRI

    We will try to explore the hypoxic fraction by use of magnetic resonance imaging

    Time frame: through study completion, an average of 1 year

  3. Health related Quality of life

    We will use EORTC-QLQ30 which is a validated instrument designed to measure quality of life in prostate cancer in both groups

    Time frame: through study completion, an average of 1 year

06

Study locations

1 site
  • University Hospital of North Norway
    Tromsø, 9038, Norway
07

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

08

Registry details

Key details

Study ID
NCT03365076
Lead sponsor
University Hospital of North Norway
Collaborators
Oslo University Hospital, University of Tromso, Northern Health Authority
Responsible party
Sponsor
First posted
Dec 7, 2017
Start date
May 1, 2018
Primary completion
Jan 5, 2023
Completion
Jan 5, 2023
Last update
Jan 9, 2023

Study contacts

Sigve Andersen, MD, PhD
principal investigator · UNN HF Tromsø

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jan 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion